Amgen’s stock falls 4% as analysts say drug updates lag competitors
The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.
The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.
